Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma

Blood blood.2024024371.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

Measurement of Serum microRNAs in US Veterans with Monoclonal Gammopathy of Undetermined Significance

Weixin Wang, PhD, Youn K Shim, PhD, Joel E Michalek, PhD, Emily Barber, BS, Layla M Saleh, MD PhD, Byeong Yeob Choi, PhD, Chen-Pin Wang, PhD, Norma Ketchum, MS, Rene Costello, MT, Gerald E Marti, MD PhD, Robert Vogt, PhD, Ola Landgren, MD PhD, Katherine R. Calvo, MD PhD

Blood (2018) 132 (Supplement 1): 5576.

https://doi.org/10.1182/blood-2018-99-114821

Published: 2018

Journal Articles

Prevalence of MBL Increases Over Time In Relatives of CLL Families,

Susan L Slager, PhD, Mark C Lanasa, MD, PhD, Sallie D. Allgood, MS, Sara J Achenbach, Aaron Norman, MS, Celine M Vachon, PhD, Lynn Goldin, PhD, Jose F. Leis, MD, PhD, Neil Kay, MD, J. Brice Weinberg, MD, Kari Rabe, MS, Timothy G. Call, MD, James R Cerhan, MD, PhD, Tait D. Shanafelt, MD, Neil E Caporaso, MD, Gerald E Marti, MD, PhD, Curtis A. Hanson, MD

Blood (2011) 118 (21): 3881.

https://doi.org/10.1182/blood.V118.21.3881.3881

Published: 2011

Journal Articles

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Blood (2010) 116 (21): 2443.

https://doi.org/10.1182/blood.V116.21.2443.2443

Published: 2010

Journal Articles

Rapid Clearance of Rituximab Contributes to the Continued High Incidence of Autoimmune Complications of Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Clifton C. Mo, MD, Mohammed Z.H. Farooqui, DO, Paul V. Beum, PhD, Ndegwa Njuguna, MD, Gerald E Marti, MD, PhD, Wyndham H. Wilson, MD, PhD, Ronald P. Taylor, PhD, Adrian U. Wiestner, MD, PhD

Blood (2010) 116 (21): 4628.

https://doi.org/10.1182/blood.V116.21.4628.4628

Published: 2010

Journal Articles

Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.

Blood (2009) 114 (22): 1232.

https://doi.org/10.1182/blood.V114.22.1232.1232

Published: 2009

Journal Articles

Multimodal Bcl-2 Sub-Populations in CLL.

Heba A. Degheidy, MD, PhD, Shahinaz M. Gadalla, MD, PhD, Elizabeth Raveche, PhD, MA Stetler-Stevenson, MD, PhD, Gerald E. Marti, MD, PhD

Blood (2009) 114 (22): 4391.

https://doi.org/10.1182/blood.V114.22.4391.4391

Published: 2009

Journal Articles

The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways

Yair Herishanu, MD, Berengere Vire, PhD, Delong Liu, PhD, Federica Gibellini, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Ndegwa Njuguna, MD, Nalini Raghavachari, PhD, Poching Liu, PhD, Stefania Pittaluga, MD, PhD, Peter J Munson, PhD, Wyndham H. Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 356.

https://doi.org/10.1182/blood.V112.11.356.356

Published: 2008

Journal Articles

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Ndegwa Njuguna, MD, Paul V Beum, PhD, Berengere Vire, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Wyndham H. Wilson, MD, PhD, Ronald P Taylor, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 4208.

https://doi.org/10.1182/blood.V112.11.4208.4208

Published: 2008

Journal Articles

Molecular Effects of Rituximab on CLL Cells In Vivo : Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression.

Adrian Wiestner, MD, PhD, Elinor Lee, BA, Berengere Vire, PhD, Federica Gibellini, PhD, Ndegwa Njuguna, MD, Yair Herishanu, MD, Delong Liu, PhD, Peter Munson, PhD, Nalini Raghavachari, PhD, Therese White, RN, Gerald E. Marti, MD, PhD, Wyndham H. Wilson, MD, PhD

Blood (2007) 110 (11): 2048.

https://doi.org/10.1182/blood.V110.11.2048.2048

Published: 2007

Journal Articles

Evidence of Pre-Diagnostic Monoclonality in Blood Obtained up to 6.4 Years Preceding Diagnosis of Chronic Lymphocytic Leukemia (CLL).

Ola Landgren, MD, PhD, Maher X. Albitar, MD, PhD, Wanlong X. Ma, PhD, Fatima R. Abbasi, PhD, Richard B. Hayes, PhD, Gerald E. Marti, MD, PhD, Neil E. Caporaso, MD

Blood (2007) 110 (11): 3082.

https://doi.org/10.1182/blood.V110.11.3082.3082

Published: 2007

Journal Articles

Rituximab Induces an Interferon Gene Expression Signature in Patients with CLL.

Elinor Lee, BA, Xiuli Xu, PhD, Peter Munson, PhD, Ronald Cooper, BA, Nalini Raghavachari, PhD, Therese White, RN, Gerald E. Marti, MD,PhD, Wyndham H. Wilson, MD,PhD, Adrian Wiestner, MD,PhD

Blood (2006) 108 (11): 4988.

https://doi.org/10.1182/blood.V108.11.4988.4988

Published: 2006

NARROW

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma

Measurement of Serum microRNAs in US Veterans with Monoclonal Gammopathy of Undetermined Significance

Prevalence of MBL Increases Over Time In Relatives of CLL Families,

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Rapid Clearance of Rituximab Contributes to the Continued High Incidence of Autoimmune Complications of Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.

Multimodal Bcl-2 Sub-Populations in CLL.

The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Molecular Effects of Rituximab on CLL Cells In Vivo : Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression.

Evidence of Pre-Diagnostic Monoclonality in Blood Obtained up to 6.4 Years Preceding Diagnosis of Chronic Lymphocytic Leukemia (CLL).

Rituximab Induces an Interferon Gene Expression Signature in Patients with CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only